Expression of epidermal growth factor-like domain 7 correlates with clinicopathological features of osteosarcoma.
Epidermal growth factor-like domain 7 gene (EGFL7) encodes an angiogenesis related factor and plays a crucial role in many human cancers. Previous studies have suggestedthat EGFL7 acts as a facilitator for tumor angiogenesis. However, little is known as to its role in osteosarcoma. Our aim was to investigate the expression of EGFL7 and to explore its correlation with the clinicopathological features of osteosarcoma. Tumor tissues from 32 Chinese young patients (below age of 24) with osteosarcoma were collected and subjected to EGFL7 detection by immunohistochemistry. The tissues from 10 patients with osteochondroma were collected and analyzed as controls. The intratumoral microvessel density (MVD) was examined by immunohistochemical staining using CD34 antibody. The results showed that patients with osteosarcoma had higher levels of EGFL7 in the tumor tissues compared to patients with osteochondroma (p<0.001). The expression of EGFL7 was significantly higher in advanced osteosarcoma (Enneking IIB-III) than that in early tumor stage (Enneking IA-IIA) (p<0.01). There is also a significant correlation between increased expression of EGFL7 and the Enneking stage (R = 0.714, p<0.001). Moreover, we detected a higher level of EGFL7 expression in tumor tissues of patients with recurrent or metastatic (bone or lung) osteosarcoma than those without recurrence or metastasis after 3 years' follow-up (p<0.01). There is no detectable difference of EGFL7 expression between tumor tissues from different tumor location and sex. Finally, we showed that high level of EGFL7expression was significantly correlated with high MVD (R = 0.829, p<0.001). In conclusion, our study demonstrates for the first time that there was a tumor grade-dependent up-regulation of EGFL7 in osteosarcoma. Elevated EGFL7 expression correlated with poor clinical outcome: i.e. advanced tumor stage, recurrent and metastatic osteosarcoma. Our findings support EGFL7 as a potential prognostic marker, and may provide novel insights for the diagnostics and therapeutics of osteosarcoma.
Department of Orthopedics, Xiangya Hospital, Central South University 87 Xiangya Road, Changsha, Hunan 410008, P.R. China.
Wei
W
Luo
Department of Orthopedics, Xiangya Hospital, Central South University 87 Xiangya Road, Changsha, Hunan 410008, P.R. China.
Changqing
C
Shao
Jiangsu Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University Zhenjiang 212013, P.R. China.
Na
N
Li
Department of Orthopedics, Xiangya Hospital, Central South University 87 Xiangya Road, Changsha, Hunan 410008, P.R. China.
Fangjie
F
Zhang
Department of Orthopedics, Xiangya Hospital, Central South University 87 Xiangya Road, Changsha, Hunan 410008, P.R. China.
Shifang
S
Guo
Department of Orthopedics, Xiangya Hospital, Central South University 87 Xiangya Road, Changsha, Hunan 410008, P.R. China.
Zhixi
Z
Duan
Jiangsu Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University Zhenjiang 212013, P.R. China ; Department of Anatomy and Cell Biology, Rush University Medical Center 600 S. Paulina Street, Room 507, Chicago, IL 60612, USA.
Qiping
Q
Zheng
Department of Orthopedics, Xiangya Hospital, Central South University 87 Xiangya Road, Changsha, Hunan 410008, P.R. China.
Hongbo
H
He
Osteosarcoma; clinicopathology; epidermal growth factor-like domain 7 (EGFL7); microvessel density (MVD); prognosis; tumor angiogenesis